Nigel Stallard
researcher
Facts
10 properties- Instance of
- human
- Occupation
- statistician
- Employer
- University of Warwick[3]
- Field of work
- medical statistics[2]
- Educated at
- University of Reading[4]
- Doctoral student
- Giorgos Minas[6]
- Maintained by WikiProject
- WikiProject Mathematics[9]
🏷️ Also known as
en Nigel Stallard
🔖 Identifiers · 7
- ISNI
- 0000000134770423
- ORCID iD
- 0000-0001-7781-1512
- OpenAlex ID
- A5090276267as of 2026-09-23
where from?
- Source
- OpenAlex
- Edition
- 20260923 · as of 2026-09-23
- Licence
- CC0 1.0 Universal
- Bronze
- not in the catalog
- Transform
- 4ort-mint · openalex:20260923 · version not recorded
- Dimensions author ID
- 01072460120.25
- Mathematics Genealogy Project ID
- 179407
- Scopus author ID
- 7004043268
- ZbMATH author ID
- stallard.nigel
📜 Data licence
Source: OpenAlex (openalex.org), snapshot of 2026-09-23. CC0 1.0 Universal. CC0 1.0 Universal · OpenAlex
🔗 Connections
Author of 11
Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial,
Comparison of Bayesian and frequentist group-sequential clinical trial designs,
DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial,
Estimation after subpopulation selection in adaptive seamless trials,
Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial,
Optimized adaptive enrichment designs,
Optimizing Trial Designs for Targeted Therapies,
Point and interval estimation in two‐stage adaptive designs with time to event data and biomarker‐driven subpopulation selection
+3 more
← Authored by 11
Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial,
Comparison of Bayesian and frequentist group-sequential clinical trial designs,
DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial,
Estimation after subpopulation selection in adaptive seamless trials,
Flexible selection of a single treatment incorporating short‐term endpoint information in a phase II/III clinical trial,
Optimized adaptive enrichment designs,
Optimizing Trial Designs for Targeted Therapies,
Point and interval estimation in two‐stage adaptive designs with time to event data and biomarker‐driven subpopulation selection
+3 more
Affiliated with 1
Press Enter · cited answer in seconds